TCGX Acquisition II is a blank check company formed to complete a merger, share exchange, asset acquisition, or similar business combination. The company has no commercial operations or revenue and focuses its search on the life sciences and medical technology sectors. TCGX Acquisition II prioritizes investment opportunities in the U.S. and Asia, with a specific focus on biopharmaceutical assets originated in China. The company is sponsored by an affiliate of TCGX, a healthcare investment firm led by Dr. Chen Yu that specializes in crossover and growth-stage life sciences investments. Under its business model, TCGX Acquisition II holds public offering proceeds in a trust account while identifying an acquisition target. The company has a 24-month window to complete a transaction. At deal completion, trust proceeds and forward purchase capital from affiliated TCGX funds finance the transaction to take the private target public. Public shareholders retain the option to redeem their capital before a deal closes. If TCGX Acquisition II does not complete a business combination within the 24-month period, it liquidates the trust and returns the capital to public shareholders.